Statistically significant immune response and recurrence rate data is the basis for new claims recently filed that GLSI-100 clinically benefits non-HLA-A*02 patients, which the Company believes ...

Get data for company analysis from the source! Learn to use investor relations pages, press releases, and financial statements to get key financial data. Dramatic video shows the moment a US fighter ...

More than 60 proposals about data centers were filed during Virginia's legislative session that ended Saturday, a barrage of bills indicative of the central role data centers now occupy in the ...

Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...

Current clinical guidelines emphasize the significance of rhythm control with catheter ablation but lack guidance on the timing of atrial fibrillation (AF) ablation relative to the diagnosis time. We ...

Abbott on Friday presented one-year clinical trial results for the Volt pulsed field ablation system alongside six-month CE mark study data for the TactiFlex Duo catheter to treat complex atrial ...

A LARGE nationwide study from the Netherlands has provided new insight into how lentigo maligna (LM) is diagnosed and treated in routine clinical practice, revealing substantial rates of tumour ...

Adding Merck & Co. and Moderna’s vaccine candidate to Keytruda has continued to cut the risk of cancer recurrence or death across five years of follow-up, boosting the companies’ prospects as they ...

LUTHER, Okla. (KFOR) — On Tuesday, the Kansas City-based energy company Transource met with residents about their energy project possibly coming to the Luther and Piedmont areas. Tuesday’s meeting was ...

At a median follow-up of 106 months, cumulative incidence of metastasis was 4.8% in the chRCC cohort, compared to 0% in the oncocytoma and ORNLMP cohorts. Oncocytomas and oncocytic neoplasms of low ...